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Abstract
Background: End stage renal disease (ESRD) is prevalent in Taiwan. Human leukocyte antigens (HLA) have been
found to be associated with the pathogenesis of autoimmune diseases, allergies and inflammatory bowel diseases,
and there are emerging evidences of correlations between HLA genotypes and renal diseases such as diabetic
nephropathy, IgA nephropathy, and glomerulonephritis. The aim of this study is to investigate detailed HLA subtypes
in a case-control study of Taiwanese individuals.
Methods: The polymorphisms of HLA class I and II antigens in ESRD patients and a healthy control group were
retrospectively analyzed. The information of 141 ESRD patients was obtained from the medical record of the Keelung
branch of Chang Gung Memorial Hospital and was compared to the HLA type of a control group comprized of 190
healthy unrelated Taiwanese from one of our previous studies. In order to standardize the HLA designation of prior
low-resolution typings with the more advanced DNA based typings, all HLA-A, −B and -DR were analyzed using a low
resolution serologic equivalent.
Results: The current work suggests that HLA-DR3 (odds ratio = 1.91, 95 % CI = 1.098–3.324, P = 0.024, Pc = 0.312) and
HLA-DR11 (odds ratio = 2.06, 95 % CI = 1.133–3.761, P = 0.021, Pc = 0.273) may represent susceptibility risk factors for the
development of ESRD in Taiwanese individuals. On the other hand, HLA-DR8 (odds ratio = 0.47, 95 % CI = 0.236–0.920,
p = 0.027. Pc = 0.351) may be a protective factor. HLA-A and -B antigens did not show any contribution of progression
to ESRD. However, we note that the significance of all these findings is lost when the results are corrected for multiple
comparisons according to Bonferroni. Further investigation with a larger group of patients and control is needed to
resolve this issue.
Conclusions: HLA typing might be a useful clinical method for screening patients with high risk of progression to
ESRD.
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Background
The prevalence and incidence of chronic kidney disease
(CKD) and end stage renal disease (ESRD) are high in
Taiwan [1], and the morbidity associated with the ESRD
has become a serious public health issue. One possible
reason is that preventive care of CKD is low in the
Taiwan [2] and the causes of CKD among Taiwanese are
diverse, the most common being diabetes mellitus, hyper-
tension, and glomerulonephritis [3]. It is worth noting that
for about 48 % of early-stage and 25 % of late-stage CKD
patients, the causes of the disease are not well defined [3].
Although no clear risk factors have been defined for these
patients it is believed that their demography and proper
access to medical care largely contribute to the lack of
prevention and poor management of CKD. Presently, the
screening of individuals without apparent symptoms or
not at risks is not applied in Taiwan [4].
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The HLA system belongs to the major histocompati-
bility complex (MHC) in humans and it is located on
chromosome 6p21.3. HLA genes encode cell surface
molecules specialized to present antigenic peptides to T-
cell receptors. MHC molecules are divided into two
main classes: MHC class I and II. The heavy chain of the
class I molecule is encoded by genes at the HLA-A,
HLA-B, and HLA-C loci, and class II MHC molecules
are encoded by genes in the HLA-DP, HLA-DQ, or
HLA-DR regions [5, 6]. Specific HLA types have been
known to be associated with the pathogenesis of many
autoimmune diseases, allergies, and inflammatory bowel
disease [7–10]. The detection of specific HLA types has
proven to be a valuable tool for the diagnosis or screen-
ing of ankylosing spondylitis, inflammatory bowel dis-
ease, and multiple sclerosis [11–13]. Several emerging
studies have described significant correlations between
HLA and some renal diseases such as diabetic nephropa-
thy, IgA nephropathy, and glomerulonephritis [14–16].
However, specific HLA types associated with ESRD
have not been well documented. In this study, HLA
class I and II polymorphisms of ESRD patients were
compared to a healthy control group in an effort to




This retrospective analysis uses data from 141 Taiwanese
ESRD patients under the age of 50 years who were
awaiting kidney transplantation between the years 2002
and 2013 at the Keelung branch of Chang Gung Memor-
ial Hospital. General clinical characteristics, HLA typing,
and causes of ESRD were obtained from the health re-
cords of the organ donation and transplantation office of
the hospital. The control group included 190 unrelated
healthy Taiwanese individuals from a previous study that
we conducted at the Mackay Memorial Hospital in
Taipei to investigate the association between HLA poly-
morphism and multibacillary leprosy [17]. All patient
and control individuals were Taiwanese, descendant of
early Minnan or Hakka Chinese from the Fukien and
Kwangton provinces on the south-east-coast of China
who settle in Taiwan in the last 400 years. Other studies
have shown that, although Minnan and Hakka speak dif-
ferent Chinese dialects, they have a similar HLA profile
[18, 19]. Allele frequencies of Minnan and Hakka in our
previous study have been deposited in a worldwide data-
base (http://www.allelefrequencies.net/). In this retro-
spective study, ethical approval was obtained by the
institutional review board of medical ethics and the hu-
man body test committee at the Chang Gung Memorial
Hospital (102-5322B).
HLA typing
HLA typing was initially performed by serological method
or DNA based typing method at the time of the onset of
the disease. The 74 ESRD patients who entered the trans-
plantation waiting list before year 2008 were typed by
complement dependent cytotoxicity (CDC) testing meth-
od,whereas the 67 ESRD patients who enrolled after the
year 2008 were typed by reverse line blot using the
RELI™ SSO typing kit (Dynal Biotech, Bromborough,
Wirral, UK). Finally, DNA-based typing results were
converted to serologic designations according to the
HLA dictionary 2008 [20].
Statistical analysis
Antigen counts were obtained from the serologic data.
Statistical analyses for the association between patient
and control groups were performed by estimating the
odds ratios (OR) and 95 % confidence intervals (95 %
CI) using the approximation method of Woolf using
GraphPadInStat version 3.0 (GraphPad Software, San
Diego, CA). Two tailed P values were estimated by Fish-
er’s exact test. A P value less or equal to 0.05 was con-
sidered to be significant. Corrected P values (Pc) were
also calculated by multiplying the P values by the num-
ber of antigens represented in the samples (according to
the Bonferroni’s correction).
Results
General characteristics of the study population
HLA polymorphism was analyzed to determine the dif-
ferences between 190 healthy control individuals and
141 ESRD patients (Table 1). Most ESRD patients had
unknown primary disease (n = 89, 63.2 %), and diabetes
mellitus type 2 was the most common cause of ESRD
(n = 30, 21.3 %).
Table 1 Baseline characteristics of the study population
Total 141
Male/Female 80 (56.7 %)/61 (43.3 %)
Mean age at the time of end stage renal
disease
40 ± 12 y
Causes of end stage renal disease
1. Diabetes mellitus 30 (21.3 %)
2. IgA nephropathy 9 (6.4 %)
3. Autosomal polycystic kidney disease 4 (2.8 %)
4. Focal segmental glomerulosclerosis 3 (2.1 %)
5. Minimal change disease 3 (2.1 %)
6. Rapidly progressive GN 1 (0.7 %)
7. Membranous nephropathy 1 (0.7 %)
8. Mesangioproliferative GN 1 (0.7 %)
9. Unknown 89 (63.2 %)
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Association of HLA-A and HLA-B antigens with ESRD
HLA class I analysis in patients and control (Table 2 and
Table 3) revealed 13 HLA-A and 28 HLA-B antigens.
The most common HLA-A locus antigens with antigen
frequency greater than 10 % in the two groups were
A11, A2, A24, and A33. Similarly, the most common
HLA-B locus antigens were B60, B46, and B58. We note
that HLA-A and -B antigens distribution in the two
groups were similar and that no significant differences
(odds ratio) were found between them.
Association of HLA-DR antigens with ESRD
The combined HLA class II polymorphism revealed 13
DR antigens (Table 4) with HLA-DR9, DR4, DR11,
DR12, DR15, DR8, DR3, DR14, and DR16 being the only
antigens having a frequency greater than 10 %. ESRD
disease assessment revealed positive associations with
HLA-DR3 (odds ratio = 1.91, 95 % CI = 1.098–3.324, P =
0.024, Pc = 0.312) and HLA-DR11 (odds ratio = 2.06,
95 % CI = 1.133–3.761, P = 0.021, Pc = 0.273), and a
negative association with HLA-DR8 (odds ratio = 0.47,
95 % CI = 0.236–0.920, P = 0.027,Pc = 0.351) (Table 4).
We note that the significance of these associations is lost
after establishing Bonferroni correction.
Most ESRD patients had unknown etiology (N = 89,
63.2 %) and only 21.3 % (N = 30) were Type II diabetes
mellitus patients. After exclusion of all DM patients
(Table 5), HLA-DR3 (OR = 1.95, P = 0.031, Pc = 0.403)
and DR11 (OR = 2.11, P = 0.030, Pc = 0.39) remained
significantly associated to ESRD whereas HLA-DR8
showed protection to the disease (OR = 0.40, P = 0.026,
Pc = 0.338). In Brief associations of DR antigens with
non-DM patients remained unchanged and further
suggest that the association of DR3 and DR11 is not
relevant to the presence or absence of DM.
Discussion
ESRD is a condition where patients are imperatively
dependent on renal replacement in order to avoid life-
threatening uremia [21]. The HLA system has been
found to be associated with the pathogenesis of auto-
immune diseases, inflammatory bowel disease, allergies
and some renal diseases such as diabetic nephropathy,
IgA nephropathy and glomerulonephritis. Identification
and analysis of the HLA polymorphism in ESRD pa-
tients is not only important for the determination of a
possible association of the disease with HLA, but is
also an absolute requirement for the selection of an op-
timal kidney matching for transplantation in these pa-
tients [22].
In this study, HLA-DR3, and HLA-DR11 antigen fre-
quencies in the ESRD patient group were significantly
higher than in the control group (DR3: cases 24.8 vs
control 14.7 %; DR11: case 21.3 vs control 11.6 %) with
OR values of 1.91 (P = 0.024) and 2.06 (P = 0.021), re-
spectively. On the other hand, HLA-DR8 was signifi-
cantly lower in the ESRD patient group than in the
control group (case 9.2 vs control 17.9 %; OR 0.47; P =
0.027). However, after Bonferroni’ correction, all cor-
rected P values were greater than 0.05 (Pc > 0.05). Al-
though the uncorrected P value may suggest type I
error, we can estimate that a data set only three times
larger would maintain significance after Bonferroni cor-
rection. Such reachable prospect justifies further ana-
lyses for confirmation of these results.
Table 2 HLA-A antigen frequency among individuals with ESRD and healthy controls
Patients N = 141 Control N = 190
Antigens Count Antigen frequency Count Antigen frequency Odds ratio 95 % confidence interval (95 % CI) P value
A1 4 2.8 % 1 0.5 % 5.52 0.610–49.920 NS
A2 61 43.3 % 96 50.5 % 0.75 0.482–1.157 NS
A3 2 1.4 % 6.83 0.325–143.350 NS
A24 48 34.0 % 59 31.1 % 1.15 0.720–1.824 NS
A11 86 61.0 % 112 58.9 % 1.09 0.698–1.699 NS
A26 5 3.5 % 10 5.3 % 0.66 0.221–1.981 NS
A29 1 0.0 % 1 0.5 % 1.35 0.084–21.771 NS
A30 7 5.0 % 3 1.6 % 3.26 0.827–12.822 NS
A31 3 2.1 % 9 4.7 % 0.44 0.116–1.645 NS
A32 2 1.1 % 0.27 0.013–5.593 NS
A33 32 22.7 % 37 19.5 % 1.21 0.712–2.069 NS
A34 3 2.1 % 9.63 0.493–187.918 NS
A68 1 0.5 % 0.45 0.018–11.040 NS
N number, NS not significant
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HLA-DR3
Previously reported associations between HLA class I
and II, and ESRD among patients with history of dia-
betes, hypertension, and various types of glomerulo-
nephritis are summarized in Table 6 [16, 23–33]. These
studies show that HLA-DR3 was significantly associ-
ated with membranous nephropathy in Chinese, French,
British, Chilean, and North American [50,51,52], DR3 was
also associated with the occurrence of diabetic nephropa-
thy [24, 29, 30, 34, 35], and was protective against the oc-
currence of idiopathic IgA nephropathy [36]. In support
to these studies, our results show that HLA-DR3 was in-
creased in the ESRD group (patients 23 vs control 14 %)
with an OR significant before Bonferroni correction.
We further note that HLA-DR11 (Table 6) was associ-
ated with diabetic nephropathy in Egyptian population
[35] and other diseases such as celiac disease, rheumatic
heart disease, and cancer [37–40]. In our study, the oc-
currence of HLA-DR11 was significantly higher in the
ESRD group. Similarly to HLA-DR3, the significance of
HLA-DR11 was lost after Bonferroni correction. Again,
while suggesting that a larger data set is required to
support to these results, one should be aware that DR3
and DR11 are potentially valuable predictors for evalu-
ating the risk of ESRD in the Taiwanese population.
HLA-DR8 has been associated with the prevalence of
DESRD in individuals under 50 years [15]. In our study,
the presence of HLA-DR8 was significantly lower in
Table 3 HLA-B antigen frequency among individuals with ESRD and healthy controls
Patients N = 141 Control N = 190
Antigens Count Antigen frequency Count Antigen frequency Odds ratio 95 % confidence interval (95 %CI) P value
B13 25 17.7 % 34 17.9 % 0.99 0.560–1.748 NS
B18 1 0.7 % 1 0.5 % 1.35 0.083–21.771 NS
B27 12 8.5 % 15 7.9 % 1.09 0.491–2.397 NS
B35 10 7.1 % 10 5.3 % 1.37 0.556–3.397 NS
B37 2 1.4 % 1 0.5 % 2.72 0.244–30.292 NS
B38 11 7.8 % 16 8.4 % 0.92 0.413–2.049 NS
B39 10 7.1 % 8 4.2 % 1.74 0.667–4.520 NS
B44 1 0.7 % 2 1.1 % 0.67 0.060–7.479 NS
B46 28 19.9 % 46 24.2 % 0.78 0.456–1.318 NS
B48 7 5.0 % 5 2.6 % 1.93 0.601–6.221 NS
B51 10 7.1 % 21 11.1 % 0.61 0.278–1.349 NS
B52 2 1.4 % 2 1.1 % 1.35 0.188–9.720 NS
B54 10 7.1 % 15 7.9 % 0.89 0.388–2.046 NS
B55 8 5.7 % 13 6.8 % 0.82 0.330–2.033 NS
B56 5 3.5 % 3 1.6 % 2.29 0.539–9.753 NS
B58 34 24.1 % 37 19.5 % 1.31 0.776–2.226 NS
B60 46 32.6 % 66 34.7 % 0.91 0.573–1.444 NS
B61 16 11.3 % 16 8.4 % 1.39 0.671–2.889 NS
B62 13 9.2 % 18 9.5 % 0.97 0.459–2.053 NS
B67 1 0.5 % 0.45 0.018–11.040 NS
B7 2 1.1 % 0.27 0.013–5.593 NS
B71 2 1.1 % 0.27 0.013–5.593 NS
B75 17 12.1 % 21 11.1 % 1.10 0.556–2.178 NS
B76 2 1.4 % 1 0.5 % 2.72 0.244–30.292 NS
B70 1 0.7 % 0 4.07 0.165–100.598 NS
B57 1 0.7 % 0 4.07 0.165–100.598 NS
B81 1 0.7 % 0 4.07 0.165–100.598 NS
B40 1 0.7 % 0 4.07 0.165–100.598 NS
N number, NS not significant
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patients than in the control group and may have a pro-
tective influence against the incidence of ESRD.
HLA-DR4
In previous studies, HLA-DR4 has been associated with
immune complex-mediated rapidly progressive glomer-
ulonephritis in populations from China, Italy and the
USA [23, 28, 32, 33] and showed strong association with
the occurrence of IgA nephropathy in the Japanese and
with idiopathic focal sclerosing glomerulosclerosis in
the Brazillian population [25, 41]. Individuals with
HLA-DR4 were also susceptible to DESRD in patients
under 50 years old from Canada [15], but was protect-
ive from diabetic nephropathy in the US and Mexican
populations [29, 34]. In this study, the frequency of
HLA-DR4 is higher in patients (34 %) than it in the
control group (28 %), but this difference was not
significant.
In brief, this study reports two HLA antigens (DR3
and DR11) that showed significant associations with the
risk of progression to ESRD. However, both control and
disease study groups were too small to sustain the sig-
nificance after Bonferonni correction. However, although
our data set was small, we find that after stratification of
our data set for non-T2DM the same level of signifi-
cance was obtained suggesting that DR3 and DR11 asso-
ciation to ESRD may be independent to any specific
disease group.
Table 4 HLA-DR antigen frequency among individuals with ESRD and healthy controls
Patients N = 141 Control N = 190
Antigens Count Antigen frequency Count Antigen frequency Odds ratio 95 % confidence interval (95 % CI) P value Corrected P value
DR1 3 1.6 % 0.19 0.010–3.695 NS
DR3 35 24.8 % 28 14.7 % 1.91 1.098–3.324 0.024 0.312
DR4 48 34.0 % 54 28.4 % 1.30 0.813–2.079 NS
DR7 9 6.4 % 4 2.1 % 3.17 0.956–10.513 NS
DR8 13 9.2 % 34 17.9 % 0.47 0.236–0.920 0.027 0.351
DR9 44 31.2 % 56 29.5 % 1.09 0.676–1.743 NS
DR10 6 4.3 % 4 2.1 % 2.07 0.572–7.466 NS
DR11 30 21.3 % 22 11.6 % 2.06 1.133–3.761 0.021 0.273
DR12 29 20.6 % 48 25.3 % 0.77 0.454–1.292 NS
DR13 6 4.3 % 17 8.9 % 0.45 0.174–1.178 NS
DR14 14 9.9 % 25 13.2 % 0.73 0.364–1.456 NS
DR15 24 17.0 % 36 18.9 % 0.88 0.496–1.551 NS
DR16 10 7.1 % 25 13.2 % 0.50 0.23–1.086 NS
N number, NS not significant
Table 5 HLA-DR antigen frequency in healthy control and non-DM individuals with ESRD
Patients (N = 111) Control (N = 190)
Antigens Count Antigen frequency Count Antigen frequency Odd ratios 95 % confidence interval (95 % CI) P value Pc value
DR1 3 1.60 % 0.24 0.012–4.694 NS
DR3 28 25.20 % 28 14.70 % 1.95 1.085–3.510 0.031 0.403
DR4 36 32.40 % 54 28.40 % 1.21 0.728–2.008 NS
DR7 8 7.20 % 4 2.10 % 3.61 1.062–12.284 0.036 0.468
DR8 9 8.10 % 34 17.90 % 0.4 0.186–0.880 0.026 0.338
DR9 35 31.50 % 56 29.50 % 1.1 0.663–1.831 NS
DR10 5 4.50 % 4 2.10 % 2.19 0.577–8.346 NS
DR11 24 21.60 % 22 11.60 % 2.11 1.118–3.970 0.03 0.39
DR12 26 23.40 % 48 25.30 % 0.9 0.523–1.565 NS
DR13 5 4.50 % 17 8.90 % 0.48 0.172–1.340 NS
DR14 11 9.90 % 25 13.20 % 0.73 0.3425–1.539 NS
DR15 17 15.30 % 36 18.90 % 0.77 0.412–1.454 NS
DR16 8 7.20 % 25 13.20 % 0.51 0.223–1.179 NS
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Table 6 Review of systemic and kidney diseases associated with HLA type
Population Study End point Susceptibility Protection Reference
MHC class I MHC class II MHC class I MHC class II
Taiwan ESRD DR3,DR11 DR8 *
Kuwaiti ESRD B8 A28 DR11 [42]
Saudi ESRD DQB1*03(8) Cw2 [43]
Glomerulonephritis













United States Anti-GBM disease DRB1*15
DRB1*04
DRB1*07 [23]
Taiwan Lupus nephritis DRB1*1202 [31]
Italy Lupus nephritis DRB1*1501,
DQA1*0101
DQA1*0102 [26]
United States IgA nephropathy B27 DR1 DR2 [44]
Japan IgA nephropathy DR4 [14]
France IgA nephropathy B35 [45]
Europe IgA nephropathy Bw35 [46]
Netherland Idiopathic IgA
nephropathy
B35 DR5 B7,B8 DR2,DR3 [36]
China IgA nephropathy DR14, DR3 DR7 [47]
Sweden IgA nephropathy DR4 [16]
France IgA nephropathy DQB1*0301 [48]
Japan IgA nephropathy Bw35 DR4 [41]
Japan IgA nephropathy DQw4 [49]
France Membranous GN DR3 [50]
Taiwan Membranous GN DR3 [51]
UnitedStates Membranous GN DR3, DR5 DR7 [52]
Netherland Idiopathic MN B8 DR3 [53]










United States Heroin- associated
nephropathy
Bw53 [55]
United States Hypertensive renal failure B35 DR3 A1, B8 [56]
Brazil Idiopathic FSGS DR4 [25]
Systemic diseases





London Early diabetic nephropathy A2 [24]
Turkey Amyloidosis and diabetic
nephropathy
B58 DR*03 [30]
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To the best of our knowledge, this analysis is the first
case–control study to analyze the association between
the HLA polymorphisms and the risk to develop ESRD
in a Taiwanese population. Further, the analysis showed
several significant DR associations with ESRD indicat-
ing that HLA class II polymorphism might be a useful
clinical tool for screening patients with high risk of
ESRD and constitute sufficient motivating elements to
undertake early preventive measures in the manage-
ment of ESRD.
Conclusion
HLA polymorphism might be a useful clinical tool for
screening patients with high risk of ESRD. This analysis
used small population case and control data set and war-
rant further study to confirm these results.
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